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Background: The extracorporeal ventricular assist device (e-VAD) system is designed for 
left ventricular support using a permanent life support console. This study aimed to deter-
mine the impact of temporary e-VAD implantation bridging on posttransplant outcomes.
Methods: We reviewed the clinical records of 6 patients with the Interagency Registry 
for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, awaiting heart trans-
plantation, who were provided with temporary e-VAD from 2018 to 2019. The circuit com-
prised a single centrifugal pump without an oxygenator. The e-VAD inflow cannula was 
inserted into the apex of the left ventricle, and the outflow cannula was positioned in the 
ascending aorta. The median follow-up duration was 8.4±6.9 months.
Results: After e-VAD implantation, lactate dehydrogenase levels significantly decreased, 
and Sequential Organ Failure Assessment scores significantly improved. Bedside rehabili-
tation was possible in 5 patients. After a mean e-VAD support duration of 14.5±17.3 days, 
all patients were successfully bridged to transplantation. After transplantation, 5 patients 
survived for at least 6 months.
Conclusion: e-VAD may reverse end-organ dysfunction and improve outcomes in INTER-
MACS I heart transplant patients.
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Introduction
The shortage of suitable donors and long waiting periods 
have resulted in a progressive increase in the number of 
candidates who are bridged to heart transplantation with 
mechanical circulatory support [1,2]. The procurement and 
distribution of donated organs in the Republic of Korea are 
coordinated by the Korean Network for Organ Sharing, a 
public healthcare network that integrates all hospitals with 
the capability for organ extraction or implantation in the 
country. In November 2018, the Health Insurance Review 
and Assessment Service approved public insurance cover-
age for durable left ventricular assist devices (LVADs; Ber-
linHeart Excor, HeartWare LVAD [HVAD]) only in pa-
tients who have been approved for a certain period of time.
Peripheral extracorporeal membrane oxygenation (p-EC-
MO) plays a major role in determining the treatment strat-
egy for patients with cardiogenic shock. It provides cardio-
respiratory support that can be used only as a short-term 
treatment. However, selected patients who fail to be 
weaned from p-ECMO may be considered for long-term 
LVADs.
Nonetheless, durable LVAD implantation is discouraged 
in patients with cardiogenic shock who are initially safely 
treated using temporary devices. In the Republic of Korea, 
temporary extracorporeal continuous-f low LVADs (e.g., 
Levitronix CentriMag, Maquet Rotaf low, Sorin Revolu-
tion) are not imported. Due to accessibility limitations, 
many heart failure teams consider transition from the 
p-ECMO system to a durable LVAD as a bridge to heart 
transplantation.
From a health insurance payer perspective, direct bridg-
ing to heart transplantation with a ventricular assist device 
appears to be more cost-effective than “double bridges” in 
patients with refractory heart failure [3]. Thus, the extra-
corporeal ventricular assist device (e-VAD) system is de-
signed for left ventricular (LV) support with a simple cir-
cuit configuration using the permanent life support (PLS) 
https://doi.org/10.5090/kjtcs.20.023
pISSN: 2233-601X   eISSN: 2093-6516
Korean J Thorac Cardiovasc Surg. 2020;53(6):368-374
369
Hyo-Hyun Kim, et al. e-VAD for INTERMACS I Patients
www.kjtcvs.org
KJTCVS
system. The e-VAD may be superior to the HVAD in terms 
of cost-effectiveness. It plays a role in the “double bridge” 
strategy when considering suitable candidates for heart 
transplantation and long-term management of patients 
with cardiogenic shock, as it is superior to p-ECMO. The 
objective of this study was to determine the impact of tem-




This study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University College of 
Medicine (IRB approval no., 4-2019-0216), and informed 
consent was obtained. We retrospectively investigated pa-
tients who underwent e-VAD implantation between Janu-
ary 2018 and September 2019.
The Interagency Registry for Mechanically Assisted Cir-
culatory Support (INTERMACS) profiles of advanced 
heart failure were defined in the setting of a multi-institu-
tional registry of VAD to clarify the clinical characteriza-
tion of heart failure patients with a failed response to con-
ventional treatment. INTERMACS has defined 7 clinical 
profiles of patients. INTERMACS profile 1 (crash and 
burn) patients should be considered for ECMO or percuta-
neous support devices [4]. Cardiogenic shock is defined as 
a cardiac index less than 2.0 L/min/m2 with a systolic 
blood pressure less than 100 mm Hg, pulmonary capillary 
wedge pressure >20 mm Hg, and dependence on 2 or more 
inotropic agents with or without an intra-aortic balloon 
pump.
The inclusion criteria for e-VAD implantation were as 
follows: (1) patients with refractory cardiogenic shock and 
multi-organ dysfunction who were expected to be removed 
from the list of candidates for heart transplantation; (2) 
those whose LV dysfunction did not improve clinically de-
spite more than 2 weeks of p-ECMO support; (3) those 
who were expected to receive p-ECMO support for more 
than 2 weeks because of old age, malnutrition, and severe 
frailty; and (4) those who had a risk of imminent death 
secondary to life-threatening recurrent ventricular ar-
rhythmia or unstable angina with life-threatening coro-
nary anatomy and severe LV dysfunction not amenable to 
revascularization, along with no known existing absolute 
contraindications to heart transplantation.
The age, sex, comorbidities, indication for e-VAD, goal 
of e-VAD treatment, and period from LVAD implantation 
to transplantation for each patient were recorded. Preoper-
ative laboratory data, including full blood count, blood 
urea nitrogen, creatinine, target international normalized 
ratio, activated partial thromboplastin time, and activated 
clotting time (ACT) were collected.
The primary outcome of this study was overall survival 
during follow-up. The secondary outcomes were postoper-
ative outcomes, including echocardiographic factors, such 
as LV end-diastolic dimension/LV end systolic dimension, 
and changes in the Sequential Organ Failure Assessment 
(SOFA) score. Additionally, we defined adverse events as 
including infection, pump failure, thrombosis, new-onset 
arrhythmia requiring pacemaker insertion, bleeding re-
quiring re-operation, respiratory complications requiring 
reintubation, acute kidney injury, and cerebrovascular ac-
cident infarction.
Surgical technique
Patients underwent e-VAD implantation through a me-
dian sternotomy. These high-risk patients were usually 
switched to cardiopulmonary bypass (CPB) machines at 
the time of VAD implantation surgery. CPB has advantages 
such as lowering blood loss in the surgical field and facili-
tating adequate filling or decompression of the left ventri-
cle (e-VAD preload). The ascending aorta and right atrium 
were cannulated to establish CPB. When an additional 
procedure, such as repair of an atrial septal defect or tri-
cuspid valve, was required, a bicaval technique was per-
formed for cannulation. The circuit was composed of a 
single centrifugal pump without an oxygenator using a PLS 
system from Maquet Medical Systems (Jostra Medizintech-
nik AG, Hirrlingen, Germany) (Fig. 1).
Two 27F venous cannulas were used to provide support. 
The LV apex was elevated by placing a long string under-
neath the heart. Double-pledgeted purse-string sutures 
were placed in the anterolateral aspect of the LV apex using 
3-0 Prolene. The heart was then volume-loaded, and CPB 
flow was decreased while a cruciate incision was made in 
the center of the purse-string sutures. The incision was 
made at a distance of 1–2 cm from the lateral side of the 
left anterior descending course. The cannula was inserted, 
and rubber sliders were tightened and secured to the can-
nula. Cannular positioning was confirmed by intraopera-
tive transesophageal echocardiography. If the inflow can-
nula was evacuated to air, it was connected to the device 
(Fig. 2). The cannula was then externalized subcostally. 
This should be done before its insertion to prevent subse-
quent inadvertent decannulation or tearing of the purse-
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string sutures (Fig. 3).
Right ventricular (RV) failure is a leading cause of mor-
tality after LVAD implantation. Thus, we were prepared to 
run temporary right-heart support using a centrifugal 
pump (RVAD) for RV failure via a left anterior mini-thora-
cotomy [5]. We performed echocardiography twice a day to 
evaluate severe right heart failure. The definition of severe 
RV failure after LVAD insertion and indications for RVAD 
implantation have been described elsewhere [6].
Anticoagulation protocol
Aspirin was administered on the operative day to all pa-
tients without postoperative bleeding. Anticoagulation was 
initiated and maintained with intravenous heparin during 
support under a cardiac index of 3.0 L/min. Patients with 
e-VAD implantation at our institution are routinely an-
ti-coagulated using aspirin and heparin, with an ACT of 
160–180 seconds. ACT was measured at 1-hour intervals 
on day 1 after surgery, and then measured at intervals of 4 
hours.
Statistical analysis
Continuous data are presented as mean±standard devia-
tion or as median and interquartile ranges (IQRs). Cate-
gorical variables were analyzed using the Fisher exact test, 
and continuous variables were evaluated using the Mann- 
Whitney U-test. The overall survival was estimated using 
Kaplan-Meier curve analysis, and differences between 
Fig. 2. (A–C) The inflow cannula was inserted into the left ventricle apex using a 27F venous cannula with a skirt made with a He-
mashield 12 mm graft. (D–F) The outflow cannula was positioned in the ascending aorta using end-to-side anastomosis under partial 
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Fig. 1. The circuit of the extracorporeal ventricular assist device 
with a single centrifugal pump and no oxygenator using the per-
manent life support system from Maquet (Jostra Medizintechnik 
AG, Hirrlingen, Germany). The inflow cannula was inserted into 
the left ventricle apex, and the outflow cannula was positioned in 
the ascending aorta.
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groups were compared using the log-rank test. For all tests, 
p-values <0.05 were considered to indicate statistical sig-
nificance. Data were analyzed using IBM SPSS ver. 25.0 
(IBM Corp., Armonk, NY, USA).
Results
Six patients underwent e-VAD implantation between 
January 2018 and September 2019. The median follow-up 
duration was 8.4±6.9 months (range, 0.7–18.0 months). Pa-
tient characteristics are shown in Table 1. The median age 
was 52.5 years (IQR, 30.8–63.8 months), and there were 
more women (66.7%) than men. Half of the patients had 
dilated cardiomyopathy, 2 patients were diagnosed with 
myocarditis (33.3%), and 1 patient (16.7%) had ischemic 
cardiomyopathy (ICMP). Five patients (83.3%) received 
mechanical ventilation, and 1 (16.7%) received non-inva-
sive ventilation preoperatively. Four patients (66.7%) had 
an implantable cardioverter defibrillator (ICD) or pace-
maker.
We immediately placed an e-VAD directly, without 
bridging with ECMO, in 2 patients (33.3%). Additionally, 4 
patients (66.7%) were switched to a left heart bypass circuit 
without an oxygenator from p-ECMO as a double bridge. 
In 3 patients (50.0%), renal failure was treated using a con-
tinuous renal replacement therapy (CRRT) device preoper-
atively (Table 2).
In all patients, emergency or urgent surgery was per-
formed. Three patients underwent concomitant proce-
dures, including atrial septal defect repair (n=2) and tricus-
pid valve repair (n=1). The mean aortic cross-clamping 
time was 92.2±8.5 minutes, and the mean CPB time was 
158.6±15.0 minutes.
After e-VAD implantation, all patients received inotropic 
support during the first few days, and most patients (83.3%) 
were weaned from inotropics 2.3±1.7 days after device im-
plantation. Extubation was successfully carried out in 3 
patients (50.0%) and O2 demand was minimized in 2 pa-
tients (33.3%). The e-VAD affected the fraction of inspired 
oxygen (FiO2) in all patients, and FiO2 significantly de-
creased postoperatively (p=0.035) (Table 3).
After surgery, 66.7% of the patients who initially received 
CRRT (2 of 3) had improved renal function and remained 
free of CRRT. On echocardiography, the left atrial volume 
index and the LV end diastolic diameter showed a tenden-
cy to decrease; however, the difference was not significant 
(p=0.780 and p=0.311, respectively). The SOFA scores sig-
nificantly decreased from 8.7±3.6 to 4.3±3.1 (p=0.048). Re-
covery of multi-organ function was seen, and bedside re-
habilitation was initiated in 5 patients (83.3%). There were 
no cases of postoperative hemorrhagic complications re-
quiring re-operation, new-onset arrhythmia, re-intubation, 
and/or wound dehiscence after e-VAD.
After e-VAD support for a mean duration of 14.5±17.3 
days (range, 2–48 days), all patients were successfully 
bridged to transplantation. The mean time from listing to 
transplantation was 45.2±32.9 days (range, 15–92 days). 
During the follow-up period after transplantation, respira-
tory failure requiring re-intubation occurred in 2 patients 
(33.3%). One patient (16.7%) required CRRT due to 
new-onset renal failure. One 49-year-old male patient died 
on postoperative day 13 due to septic shock caused by 
pneumonia. The patient had ICMP with an ICD device. In 
Kaplan-Meier analysis, the 6-month survival rate was 
83.3% (Fig. 4).
Discussion
In this study, we demonstrated that e-VAD can provide 
Fig. 3. (A, B) The inflow and outflow cannulae were placed through 
the left subcostal margin via a subcutaneous tunnel. Written in-





Table 1. Baseline characteristics of patients
Characteristic Value
Age (yr) 52.5
Female sex 4 (66.6)
Body surface area (m2) 1.64
Dilated cardiomyopathy 3 (50.0)
Myocarditis 2 (33.3)
Ischemic cardiomyopathy 1 (16.7)
Hypertension 2 (33.3)
Diabetes mellitus 1 (16.7)
Chronic renal failure 0
Smoking history 1 (16.7)
Values are presented as median or number (%).
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LV unloading and circulatory support for patients with 
INTERMACS profile 1. The success rate of bridging to 
transplantation in this cohort of 6 patients was 100%. 
Pump performance data indicated satisfactory hemody-
namic support that was sufficient to meet the shock pa-
tients’ circulatory needs. The benefits associated with 
e-VAD include ease of implantation, adequate ventricular 
unloading, reliable device function, no requirement for 
prior approval, and a low incidence of device-related com-
plications compared to p-ECMO. The 6-month survival of 
these patients was 83.3%; thus, these outcomes support 
conditions conducive to recovery from cardiogenic shock.
Despite many advances in the management of patients 
with acute heart failure, the outcomes for patients with re-
fractory acute cardiogenic shock remain poor [7,8]. Fur-
thermore, in the Republic of Korea, these patients do not 
have access to advanced circulatory support technologies 
or the resources to manage them because there is no avail-
able temporary e-VAD device on the market. Delay in re-
ferral to tertiary centers further exacerbates the poor out-
comes in this group of patients. Therefore, there is a need 
for the wider application of temporary circulatory support 
in such patients.
The primary hemodynamic goals of e-VAD are to de-
crease the preload, decrease the afterload, and augment the 
cardiac output. The end goal is to provide adequate organ 
perfusion and oxygen delivery, which can bridge patients 
to recovery or a more durable device, and can also support 
them through high-risk procedures [9,10]. Temporary 
e-VAD can be used to mechanically unload the LV with 
concomitant ECMO to replace pulmonary gas exchange. 
However, ECMO does not unload the ventricles to the de-
gree possible with an LVAD and has a high rate of de-
vice-related complications [11]. Moreover, ECMO requires 
the patient to be immobilized. Other commercially avail-
able extracorporeal devices have major disadvantages, such 
as a large priming volume, limited duration of use, throm-
boembolic risk, and device size [12-14]. This study high-
lights the recovery of organ dysfunction and ambulation 
after e-VAD, with implications for the selection of the best 
short-term circulatory assist system for acute cardiogenic 
shock or while sliding on inotropes.
Kashiwa et al. [15] reported a case in which left heart by-
pass support with the Rotaflow centrifugal pump was per-
formed as a bridge to transplantation decision and recov-
ery. Of note, the pump could be used continuously for 
more than 30 days [15]. In the present study, e-VAD was 
used as a bridge to transplantation in a 72-year-old female 
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serving as a bridge to long-term support in patients who 
continue to have unresolved end-organ dysfunctions 
during ECMO support. Thus, we demonstrated that e-VAD 
can be used as a durable long-term device for patients 
awaiting transplantation.
ECMO is well known to result in coagulopathy, continu-
ous activation of the contractile and fibrinolytic systems by 
the circuit, and consumption and dilution of factors. This 
occurs within minutes of initiation of ECMO. However, 
systemic heparinization is still advisable because due to the 
risk of end-organ damage from microthrombus and fibrin 
deposition [16]. Moubarak et al. [17] reported a massive in-
traventricular thrombus in a patient on ECMO under hep-
arinization, and thrombus formation may be increased by 
the unloading of cardiac chambers observed with LVADs. 
Thus, we provided our patients with low levels of heparin 
and aspirin to prevent clotting of both cannulae, tubing, 
and the bearing of the centrifugal pump. In this study, no 
thrombus formation was found in the cannula and circuit 
tube. Heparin and concurrent use of an antiplatelet agent 
(aspirin) might be considered to further prevent thrombus 
formation. Furthermore, a simple circuit configuration 
Table 3. Procedure-related details and changes in hemodynamic/laboratory parameters after assembled extracorporeal VAD
Characteristic Preoperative Postoperative p-value
LVEF (%) 20.2±10.7 20.7±9.1 0.899
LAVI (mL/m2) 64.1±32.7 56.6±31.8 0.780
LVEDD (mm) 62.7±13.6 57.2±14.8 0.311
LVESD (mm) 55.5±15.1 52.2±17.8 0.506
RVSP (mm Hg) 46.5±19.6 42.3±8.4 0.812
Blood urea nitrogen (mg/dL) 26.5±17.5 31.2±24.2 0.433
Creatinine (mg/dL) 0.9±0.3 0.9±0.4 0.409
Glomerular filtration rate (MDRD) 77.0±22.0 57.5±26.1 0.311
Total bilirubin (mg/dL) 17.8±23.7 2.4±0.8 0.172
AST (IU/L) 138.7±196.9 71.0±74.6 0.696
ALT (IU/L) 136.3±45.2 44.5±45.2 0.355
Amylase (U/L) 68.5±36.7 89.3±51.8 0.415
Lipase (U/L) 121.0±118.8 66.5±56.3 0.086
Lactate (mmol/L) 2.0±1.2 2.0±1.1 0.697
LDH (IU/L) 2,457.7±220.8 671.3±32.5 <0.001
PT (INR) 1.2±0.2 1.3±0.1 0.999
SOFA score 8.7±3.6 4.3±3.1 0.048
PaO2 (mm Hg) 146.9±85.6 186.8±55.9 0.425
FiO2 (%) 70.0±32.9 30.0±8.9 0.035
On mechanical ventilation 5 (83.3) 2 (33.3) 0.180
Platelets (103/µL) 112.7±34.7 140.2±64.0 0.403
Glasgow Coma Scale 12.2±1.8 13.7±2.1 0.304
Bilirubin (mg/dL) 6.9±13.0 2.5±0.7 0.047
Administration of vasoactive agents required 6 (100.0) 1 (16.7) 0.025
Continuous renal replacement therapy 3 (50.0) 1 (16.7) 0.157
Values are presented as mean±standard deviation or number (%).
VAD, ventricular assist device; LVEF, left ventricular ejection fraction (%); LAVI, left atrial volume index (mL/m2); LVEDD, left ventricular end-
diastolic dimension (mm); LVESD, left ventricular end systolic dimension (mm); RVSP, right ventricular systolic pressure; MDRD, Modification of 
Diet in Renal Disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; PT, prothrombin time; INR, 
international normalized ratio; SOFA, Sequential Organ Failure Assessment; PaO2, partial pressure of oxygen; FiO2, fraction of inspired oxygen.
Fig. 4. Kaplan-Meier survival analysis of e-VAD implantation. 

































without branches may also help prevent thrombus forma-
tion.
The present study has several limitations. First, a major 
limitation of this study is the relatively small sample size. 
Second, this study was a retrospective analysis of observa-
tional data. Third, the study population did not include a 
control group. Lastly, there remains potential variation 
among patients regarding antibiotic protocols and the 
management of postoperative complications.
We have demonstrated that e-VAD using an assembled 
PLS circuit can provide effective LV support for patients 
with medically refractory acute cardiogenic shock to opti-
mize heart transplantation with acceptable survival.
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